| EN
Simcere has been continuously expanding its R&D investments. In 2022, its R&D investment was more than CNY 1.7 billion, accounting for 27.3% of the sales revenue.
With five R&D centers in Shanghai, Nanjing, Beijing, Boston and HongKong, the company has established a whole-process R&D system integrating drug discovery, pre-clinical development, clinical trials, and drug registration.
Additionally, the company has established an R&D team comprising over 1000 professionals, of whom more than 60% are professionals with a master's or doctoral degree and more than 10% are professionals with an international education background.

Global R&D Center Layout

Boston R&D Center

Nanjing R&D Center

Shanghai R&D Center

R&D Pipeline

We have nearly 60 innovative product candidates in different stages of development, among which over 10 product candidates had obtained the IND approval or were at clinical stage.


Massachusetts is home to 19% of the top pharmaceutical product pipelines in the United States and 9% globally. The state capital, Boston, in particular holds a dominating position in the global life sciences community.

Simcere’s Boston R&D Center focuses on the world's cutting-edge cell and gene therapies, and with its team of pioneering scientists, it remains dedicated to building a world-class R&D center. Utilizing the world's state-of-the-art technologies, we are rapidly building several cutting-edge technology platforms for cell and gene therapies and thereby making the Boston R&D Center a powerful pipeline driver for Simcere through the institute’s fast and efficient project promotion system.